{"id":454,"date":"2023-04-04T09:33:11","date_gmt":"2023-04-04T09:33:11","guid":{"rendered":"https:\/\/www.cic.vc\/?p=454"},"modified":"2024-04-16T12:12:25","modified_gmt":"2024-04-16T12:12:25","slug":"oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo","status":"publish","type":"post","link":"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/","title":{"rendered":"Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO"},"content":{"rendered":"

The Wellcome Sanger Institute\u2019s latest oncology spinout will enter the clinic in about 18 to 24 months with a new CEO at the helm and $28 million in Series A funds.<\/span><\/p>\n

Called Mosaic Therapeutics, the startup is working on new targeted treatments from the labs of Sanger\u2019s Mathew Garnett and Sanofi board member Emile Voest, who works at the Netherlands Cancer Institute and Oncode Institute. Also on the co-founding team is former Sanger head of technology translation Adrian Ibrahim.<\/span><\/p>\n

The 25-employee, UK-based biotech has recruited Brian Gladsden, a two-decade Novartis veteran and former SVP, as CEO.<\/span><\/p>\n

Mosaic is using experimental biology and computational methods to make new cancer drugs.<\/span><\/p>\n

\u201cWithin oncology and having spent a long time in oncology, we know the challenges there,\u201d Gladsden said in an interview. His most recent role at Novartis was running worldwide commercial and portfolio strategy. \u201cYou still see that five-year survival rates across all cancer types are still sitting at around 50%-51%, and the clinical failure rate in oncology is around 93% and it\u2019s been very much a needle-in-a-haystack type of approach.\u201d<\/span><\/p><\/blockquote>\n

He called the opportunity at Mosaic \u201ctoo exciting to pass up,\u201d pointing to the expertise and work of the founding scientists, including Garnett\u2019s work helping identify BRAF as a cancer gene.<\/span><\/p>\n

\u201cWe\u2019re not looking at specific tumor types and saying, \u2018Let\u2019s go find a target there,’\u201d Gladsden said. \u201cWe\u2019re trying to identify using a very unbiased method looking at large screens and large datasets about where we think that either single target or combinations can have the greatest impact.\u201d<\/span><\/p>\n

Formed in 2020, the biotech was originally seeded by Innovate UK. The Series A comes from Cambridge Innovation Capital and Syncona Investment Management. The UK life sciences investor last year helped launch Forcefield Therapeutics, brought Applied Genetic Technologies Corporation into its fold and further invested in gene therapy biotech SwanBio.<\/span><\/p>\n

Mosaic is the latest company to form out of Sanger\u2019s work. The institute, which contributed to the Human Genome Project, has also formed genomic analysis company Congenica, microbiome-focused Microbiotica, Sanofi-acquired Kymab and VHsquared, an inflammatory bowel disease startup that wound down last year.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

The Wellcome Sanger Institute\u2019s latest oncology spinout will enter the clinic in about 18 to 24 months with a new CEO at the helm and $28 million in Series A funds. Called Mosaic Therapeutics, the startup is working on new targeted treatments from the labs of Sanger\u2019s Mathew Garnett and Sanofi board member Emile Voest, […]<\/p>\n","protected":false},"author":5,"featured_media":1243,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[6,29],"tags":[50],"acf":[],"yoast_head":"\nOncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO - Cambridge Innovation Capital<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO - Cambridge Innovation Capital\" \/>\n<meta property=\"og:description\" content=\"The Wellcome Sanger Institute\u2019s latest oncology spinout will enter the clinic in about 18 to 24 months with a new CEO at the helm and $28 million in Series A funds. Called Mosaic Therapeutics, the startup is working on new targeted treatments from the labs of Sanger\u2019s Mathew Garnett and Sanofi board member Emile Voest, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/\" \/>\n<meta property=\"og:site_name\" content=\"Cambridge Innovation Capital\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T09:33:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-16T12:12:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Cancer-cell-target-AdobeStock_534771053-1-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1415\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Colin Berwick\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@cic_vc\" \/>\n<meta name=\"twitter:site\" content=\"@cic_vc\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Colin Berwick\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/\",\"url\":\"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/\",\"name\":\"Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO - Cambridge Innovation Capital\",\"isPartOf\":{\"@id\":\"https:\/\/www.cic.vc\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Cancer-cell-target-AdobeStock_534771053-1-scaled.jpeg\",\"datePublished\":\"2023-04-04T09:33:11+00:00\",\"dateModified\":\"2024-04-16T12:12:25+00:00\",\"author\":{\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/2a0fb039a2a216c26fcd56ba96b54734\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/#primaryimage\",\"url\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Cancer-cell-target-AdobeStock_534771053-1-scaled.jpeg\",\"contentUrl\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Cancer-cell-target-AdobeStock_534771053-1-scaled.jpeg\",\"width\":2560,\"height\":1415,\"caption\":\"Targeted Cell Therapy - Treatments that Use Drugs Designed to Target Anomalous Cells without Affecting Healthy Cells - Conceptual Illustration\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cic.vc\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cic.vc\/#website\",\"url\":\"https:\/\/www.cic.vc\/\",\"name\":\"Cambridge Innovation Capital\",\"description\":\"We enable visionaries to build global, category-leading companies.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cic.vc\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/2a0fb039a2a216c26fcd56ba96b54734\",\"name\":\"Colin Berwick\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e7f6d32e9af553e4e969350cc5adddbb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e7f6d32e9af553e4e969350cc5adddbb?s=96&d=mm&r=g\",\"caption\":\"Colin Berwick\"},\"url\":\"https:\/\/www.cic.vc\/author\/colin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO - Cambridge Innovation Capital","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/","og_locale":"en_GB","og_type":"article","og_title":"Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO - Cambridge Innovation Capital","og_description":"The Wellcome Sanger Institute\u2019s latest oncology spinout will enter the clinic in about 18 to 24 months with a new CEO at the helm and $28 million in Series A funds. Called Mosaic Therapeutics, the startup is working on new targeted treatments from the labs of Sanger\u2019s Mathew Garnett and Sanofi board member Emile Voest, […]","og_url":"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/","og_site_name":"Cambridge Innovation Capital","article_published_time":"2023-04-04T09:33:11+00:00","article_modified_time":"2024-04-16T12:12:25+00:00","og_image":[{"width":2560,"height":1415,"url":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Cancer-cell-target-AdobeStock_534771053-1-scaled.jpeg","type":"image\/jpeg"}],"author":"Colin Berwick","twitter_card":"summary_large_image","twitter_creator":"@cic_vc","twitter_site":"@cic_vc","twitter_misc":{"Written by":"Colin Berwick","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/","url":"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/","name":"Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO - Cambridge Innovation Capital","isPartOf":{"@id":"https:\/\/www.cic.vc\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/#primaryimage"},"image":{"@id":"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Cancer-cell-target-AdobeStock_534771053-1-scaled.jpeg","datePublished":"2023-04-04T09:33:11+00:00","dateModified":"2024-04-16T12:12:25+00:00","author":{"@id":"https:\/\/www.cic.vc\/#\/schema\/person\/2a0fb039a2a216c26fcd56ba96b54734"},"breadcrumb":{"@id":"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/#primaryimage","url":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Cancer-cell-target-AdobeStock_534771053-1-scaled.jpeg","contentUrl":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Cancer-cell-target-AdobeStock_534771053-1-scaled.jpeg","width":2560,"height":1415,"caption":"Targeted Cell Therapy - Treatments that Use Drugs Designed to Target Anomalous Cells without Affecting Healthy Cells - Conceptual Illustration"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cic.vc\/oncology-startup-from-sanger-institute-nabs-28m-ex-novartis-svp-as-ceo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cic.vc\/"},{"@type":"ListItem","position":2,"name":"Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO"}]},{"@type":"WebSite","@id":"https:\/\/www.cic.vc\/#website","url":"https:\/\/www.cic.vc\/","name":"Cambridge Innovation Capital","description":"We enable visionaries to build global, category-leading companies.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cic.vc\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.cic.vc\/#\/schema\/person\/2a0fb039a2a216c26fcd56ba96b54734","name":"Colin Berwick","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.cic.vc\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e7f6d32e9af553e4e969350cc5adddbb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e7f6d32e9af553e4e969350cc5adddbb?s=96&d=mm&r=g","caption":"Colin Berwick"},"url":"https:\/\/www.cic.vc\/author\/colin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/454"}],"collection":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/comments?post=454"}],"version-history":[{"count":9,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/454\/revisions"}],"predecessor-version":[{"id":6788,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/454\/revisions\/6788"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/media\/1243"}],"wp:attachment":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/media?parent=454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/categories?post=454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/tags?post=454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}